Chlorotrianisene

Chlorotrianisene (CTA) (INN, USAN, BAN) (brand names Tace, Estregur, Anisene, Clorotrisin, Merbentyl, Triagen, many others), also known as tri-p-anisylchloroethylene (TACE) or as tris(p-methoxyphenyl)chloroethylene, is a synthetic, non-steroidal estrogen of the triphenylethylene group that was formerly used for the treatment of menopausal symptoms, estrogen deficiency, and prostate cancer before being discontinued. It was approved in the United States as TACE in 1952, and was introduced throughout Europe subsequently. CTA was the first estrogenic compound of the triphenylethylene series to be introduced.